<DOC>
	<DOCNO>NCT00899470</DOCNO>
	<brief_summary>To demonstrate bioequivalence 2.5 mg saxagliptin/500 mg metformin ( glucophage ) immediate release ( IR ) fix dose combination ( FDC ) tablet 2.5 mg saxagliptin tablet 500 mg metformin IR tablet co-administered healthy subject fast fed state .</brief_summary>
	<brief_title>Bioequivalence Study Saxagliptin Glucophage Combination Formulations Healthy Subjects ( A )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Men woman age 19 45 inclusive Healthy subject determine clinically significant deviation normal medical history , physical examination , electrocardiogram ( ECGs ) , clinical laboratory determination Body Mass Index ( BMI ) 18 32 kg/m2 , inclusive . BMI = weight ( kg ) / [ height ( ) ] 2 Women childbearing potential ( WOCBP ) unwilling unable use acceptable barrier method ( condom spermicide ) avoid pregnancy entire study period 8 week last dose investigational product Any significant acute chronic medical illness Current recent ( within 3 month ) gastrointestinal disease Any major surgery within 4 week study drug administration History allergy Dipeptidyl peptidase 4 ( DPP4 ) inhibitor related compound History allergy intolerance metformin similar acting agent Prior exposure saxagliptin Prior exposure metformin within 3 month study drug administration . Estimated creatinine clearance ( Clcr ) &lt; 80ml/min use Cockcroft Gault formula</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>